JOIN US

SHARED COMMITMENT TO A COMPLEX SCIENCE.

Curing pediatric cancer is such a big and complex challenge, it’s unrealistic to think that any one pediatric center can get the job done alone. By working together in a coordinated way, we can accomplish more, with greater benefits, at lower costs.

As a member, your institution will be able to participate in the CureWorks pipeline and provide innovative immunotherapies directly to your patients. This allows you to treat more patients locally, while redefining the standard of care globally. Members benefit from access to an array of technologies, data, and expertise, including clinical trial coordination and manufacturing of individual treatments.

CAPABILITIES

We are building an organization and a pipeline that will continuously push the bounds of scientific discovery in pursuit of cures. We see a world where there is no chemo, no radiation, and finally, no pediatric cancer.

SEE OUR PIPELINE

29,000


Square feet of manufacturing space (in 2020)

500


GMP grade engineered cell products per year (in 2020)

11


Trials Currently in pipeline


BECOME A MEMBER

We are looking for institutions that share our commitment to expanding access to these promising cures for children. To learn more about becoming a participating institution, please contact us at info@cureworks.org


ACADEMIC PUBLICATIONS

Learn more about our science and progress.

Preclinical Assessment of CD171-Directed CAR T-cell Adoptive Therapy for Childhood Neuroblastoma: CE7 Epitope Target Safety and Product Manufacturing FeasibilityClinical Cancer Research

Clinical Cancer Research

Neuroblastoma is the most common extracranial solid tumor of childhood with a heterogeneous clinical course. While neuroblastomas with favorable biology spontaneously regress or differentiate without therapeutic intervention, neuroblastomas with unfavorable biology often fatally progress despite intensive multimodal therapy.

READ MORE

Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy

The New England Journal of Medicine

Glioblastoma, an aggressive primary brain tumor, is among the most lethal of human cancers. We present evidence of the potential therapeutic benefit of adoptive T-cell therapy against glioblastoma with the use of CAR-engineered T cells targeting IL13Rα2, a glioma-associated antigen linked to a reduced rate of survival.

READ MORE

Designing chimeric antigen receptors to effectively and safely target tumors

Clinical Cancer Research

The adoptive transfer of T cells engineered to express artificial chimeric antigen receptors CARs) that target a tumor cell surface molecule has emerged as an exciting new approach for cancer immunotherapy. Clinical trials in patients with advanced B cell malignancies treated with CD19-specific CAR-modified T cells (CAR-T) have shown impressive antitumor efficacy, leading to optimism that this approach will be useful for treating common solid tumors.

READ MORE

Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults

Pub Med Central

CD19-specific chimeric antigen receptor (CAR)–expressing autologous T cells administered after lymphodepleting chemotherapy can induce clinical remissions in B-lineage malignancies, including refractory pediatric acute lymphoblastic leukemia (ALL), irrespective of disease burden or anatomic dissemination.

READ MORE

TOP